DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia
Lonneke Verboon, Sonali P. Barwe, Meredith Tavenner, Joshua R. Faust, Hasan Issa, José Gonçalves-Dias, K. Schuschel, Raj Bhayadia, Patrick H. van Berkel, Aimy Sebastian, Rhonda E. Ries, Sophie Paczesny, Soheil Meshinchi, Johann K. Hitzler, Yana Pikman, , Anilkumar Gopalakrishnapillai
This study identifies DLK1 as a GATA1s-driven dependency in Down syndrome-associated myeloid leukemia, showing it as a therapeutic target with preclinical efficacy in PDX models.
Blood Advances · Apr 7, 2026Peer-reviewedCancer Biology